ARS Pharmaceuticals, Inc. SPRY Debt-to-equity

Debt-to-equity at other companies

Amneal Pharmaceuticals, Inc.AMRX

77.8×—

ViatrisVTRS

1×0.0×

Neuropace, Inc.NPCE

4.9×+1.9×

Eton Pharmaceuticals, Inc.ETON

1×-0.2×

FAQ

What is ARS Pharmaceuticals, Inc.'s debt-to-equity?

ARS Pharmaceuticals, Inc. (SPRY) reported debt-to-equity of 1.6× in Q1 2026.

How has ARS Pharmaceuticals, Inc.'s debt-to-equity changed year-over-year?

ARS Pharmaceuticals, Inc.'s debt-to-equity increased by 524700.0% year-over-year, from 0× to 1.6×.

What is the long-term trend for ARS Pharmaceuticals, Inc.'s debt-to-equity?

Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s debt-to-equity has grown at a 676.7% compound annual growth rate (CAGR), from 0× to 0.8×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.